Viracor-IBT agrees to buy Cylex’s assets
EnlargeViracor-IBT Laboratories Inc. is based in Lee's Summit.
Brianne Pfannenstiel
Reporter-
Kansas City Business Journal
Email | Twitter | Health Care Viracor-IBT Laboratories Inc. expects to close Friday on its agreement to buy the assets of Cylex Inc. for an undisclosed amount.
Lee’s Summit-based Viracor-IBT is a specialty diagnostics laboratory in immunology, infectious disease and allergy testing. Cylex is a global life sciences company.
With its purchase of Cylex, announced Tuesday, Viracor-IBT also will acquire Cylex’s core product, ImmuKnow. ImmuKnow assesses cellular immune status and can be used to help identify kidney, liver, lung and heart transplant patients with low immune response, which can lead to infection.
Viracor-IBT has offered ImmuKnow to its clients for nearly a decade, a news release said.
“We’re confident this acquisition will result in continued benefits to the industry, our clients and to the patients we serve,” Viracor-IBT CEO Thomas Burnell said in the release. “Throughout the transition, Viracor-IBT is committed to ensuring continued access to ImmuKnow through the current avenues of kit purchases and laboratory testing,”
Cylex is focused on developing and manufacturing in vitro diagnostic products intended to assess immune cell function and provide insight for individualized transplant patient management.
ViraCor Laboratories and IBT Laboratories merged in 2009, creating a then 200-employee lab.
Brianne covers health care, life sciences, animal health and biosciences.
Related links:Lee’s Summit